Increased risk of diabetes mellitus and hyperlipidemia in patients with differentiated thyroid cancer
CONCLUSIONS: Patients with DTC had an increased risk of CMD, especially DM and hyperlipidemia, but a low risk of CMD mortality. Special attention to metabolic diseases is required in the long-term follow-up of patients with DTC.PMID:38536878 | DOI:10.1093/ejendo/lvae026 (Source: European Journal of Endocrinology)
Source: European Journal of Endocrinology - March 27, 2024 Category: Endocrinology Authors: Hwa Young Ahn Jooyoung Lee Jinmo Kang Eun Kyung Lee Source Type: research

Directed Acyclic Graphs (DAGs) in clinical research
Eur J Endocrinol. 2024 Mar 26:lvae032. doi: 10.1093/ejendo/lvae032. Online ahead of print.ABSTRACTDirected acyclic graphs (DAGs), or causal diagrams, are graphical representations of causal structures that can be used in medical research to understand and illustrate potential bias, including bias arising from confounding, selection, and misclassification. Further, they provide guidance for researchers about how to address a potential bias.PMID:38529789 | DOI:10.1093/ejendo/lvae032 (Source: European Journal of Endocrinology)
Source: European Journal of Endocrinology - March 26, 2024 Category: Endocrinology Authors: Olaf M Dekkers Kristina Laugesen Rolf H H Groenwold Source Type: research

Directed Acyclic Graphs (DAGs) in clinical research
Eur J Endocrinol. 2024 Mar 26:lvae032. doi: 10.1093/ejendo/lvae032. Online ahead of print.ABSTRACTDirected acyclic graphs (DAGs), or causal diagrams, are graphical representations of causal structures that can be used in medical research to understand and illustrate potential bias, including bias arising from confounding, selection, and misclassification. Further, they provide guidance for researchers about how to address a potential bias.PMID:38529789 | DOI:10.1093/ejendo/lvae032 (Source: European Journal of Endocrinology)
Source: European Journal of Endocrinology - March 26, 2024 Category: Endocrinology Authors: Olaf M Dekkers Kristina Laugesen Rolf H H Groenwold Source Type: research

Central precocious puberty in boys: secular trend and clinical features
CONCLUSIONS: The estimated incidence of CPP in boys was 0.34 per 10 000, with 26% of cases associated with intracranial pathology. The increase in CPP incidence was driven by rising ICPP rates. Patients with OCPP were characterized by shorter stature, younger age, and higher basal testosterone levels, providing valuable cues for differentiation in addition to brain MRI. Utilizing multiple cues could guide diagnostic decision-making.PMID:38523472 | DOI:10.1093/ejendo/lvae021 (Source: European Journal of Endocrinology)
Source: European Journal of Endocrinology - March 25, 2024 Category: Endocrinology Authors: Heta Huttunen Juho K ärkinen Tero Varimo P äivi J Miettinen Taneli Raivio Matti Hero Source Type: research

Real-world experience with 11C-methionine PET in the management of acromegaly
CONCLUSION: In patients with persistent/recurrent acromegaly or occult tumours, Met-PET can facilitate further targeted intervention (surgery/radiosurgery). This led to complete remission in most cases (24/33) or significant improvement with comparatively low risk of complications. Met-PET should therefore be considered in all patients who are potential candidates for further surgical intervention, but present no clear target on MRI.PMID:38482632 | DOI:10.1093/ejendo/lvae028 (Source: European Journal of Endocrinology)
Source: European Journal of Endocrinology - March 14, 2024 Category: Endocrinology Authors: Linus Haberbosch James MacFarlane Olympia Koulouri Daniel Gillett Andrew S Powlson Sue Oddy David J Halsall Kevin A Huynh Jonathan Jones Heok K Cheow Joachim Spranger Knut Mai Christian Strasburger Richard J Mannion Mark Gurnell Source Type: research

Real-world experience with 11C-methionine PET in the management of acromegaly
CONCLUSION: In patients with persistent/recurrent acromegaly or occult tumours, Met-PET can facilitate further targeted intervention (surgery/radiosurgery). This led to complete remission in most cases (24/33) or significant improvement with comparatively low risk of complications. Met-PET should therefore be considered in all patients who are potential candidates for further surgical intervention, but present no clear target on MRI.PMID:38482632 | DOI:10.1093/ejendo/lvae028 (Source: European Journal of Endocrinology)
Source: European Journal of Endocrinology - March 14, 2024 Category: Endocrinology Authors: Linus Haberbosch James MacFarlane Olympia Koulouri Daniel Gillett Andrew S Powlson Sue Oddy David J Halsall Kevin A Huynh Jonathan Jones Heok K Cheow Joachim Spranger Knut Mai Christian Strasburger Richard J Mannion Mark Gurnell Source Type: research

Real-world experience with 11C-methionine PET in the management of acromegaly
CONCLUSION: In patients with persistent/recurrent acromegaly or occult tumours, Met-PET can facilitate further targeted intervention (surgery/radiosurgery). This led to complete remission in most cases (24/33) or significant improvement with comparatively low risk of complications. Met-PET should therefore be considered in all patients who are potential candidates for further surgical intervention, but present no clear target on MRI.PMID:38482632 | DOI:10.1093/ejendo/lvae028 (Source: European Journal of Endocrinology)
Source: European Journal of Endocrinology - March 14, 2024 Category: Endocrinology Authors: Linus Haberbosch James MacFarlane Olympia Koulouri Daniel Gillett Andrew S Powlson Sue Oddy David J Halsall Kevin A Huynh Jonathan Jones Heok K Cheow Joachim Spranger Knut Mai Christian Strasburger Richard J Mannion Mark Gurnell Source Type: research

Real-world experience with 11C-methionine PET in the management of acromegaly
CONCLUSION: In patients with persistent/recurrent acromegaly or occult tumours, Met-PET can facilitate further targeted intervention (surgery/radiosurgery). This led to complete remission in most cases (24/33) or significant improvement with comparatively low risk of complications. Met-PET should therefore be considered in all patients who are potential candidates for further surgical intervention, but present no clear target on MRI.PMID:38482632 | DOI:10.1093/ejendo/lvae028 (Source: European Journal of Endocrinology)
Source: European Journal of Endocrinology - March 14, 2024 Category: Endocrinology Authors: Linus Haberbosch James MacFarlane Olympia Koulouri Daniel Gillett Andrew S Powlson Sue Oddy David J Halsall Kevin A Huynh Jonathan Jones Heok K Cheow Joachim Spranger Knut Mai Christian Strasburger Richard J Mannion Mark Gurnell Source Type: research

Real-world experience with 11C-methionine PET in the management of acromegaly
CONCLUSION: In patients with persistent/recurrent acromegaly or occult tumours, Met-PET can facilitate further targeted intervention (surgery/radiosurgery). This led to complete remission in most cases (24/33) or significant improvement with comparatively low risk of complications. Met-PET should therefore be considered in all patients who are potential candidates for further surgical intervention, but present no clear target on MRI.PMID:38482632 | DOI:10.1093/ejendo/lvae028 (Source: European Journal of Endocrinology)
Source: European Journal of Endocrinology - March 14, 2024 Category: Endocrinology Authors: Linus Haberbosch James MacFarlane Olympia Koulouri Daniel Gillett Andrew S Powlson Sue Oddy David J Halsall Kevin A Huynh Jonathan Jones Heok K Cheow Joachim Spranger Knut Mai Christian Strasburger Richard J Mannion Mark Gurnell Source Type: research

Real-world experience with 11C-methionine PET in the management of acromegaly
CONCLUSION: In patients with persistent/recurrent acromegaly or occult tumours, Met-PET can facilitate further targeted intervention (surgery/radiosurgery). This led to complete remission in most cases (24/33) or significant improvement with comparatively low risk of complications. Met-PET should therefore be considered in all patients who are potential candidates for further surgical intervention, but present no clear target on MRI.PMID:38482632 | DOI:10.1093/ejendo/lvae028 (Source: European Journal of Endocrinology)
Source: European Journal of Endocrinology - March 14, 2024 Category: Endocrinology Authors: Linus Haberbosch James MacFarlane Olympia Koulouri Daniel Gillett Andrew S Powlson Sue Oddy David J Halsall Kevin A Huynh Jonathan Jones Heok K Cheow Joachim Spranger Knut Mai Christian Strasburger Richard J Mannion Mark Gurnell Source Type: research

Real-world experience with 11C-methionine PET in the management of acromegaly
CONCLUSION: In patients with persistent/recurrent acromegaly or occult tumours, Met-PET can facilitate further targeted intervention (surgery/radiosurgery). This led to complete remission in most cases (24/33) or significant improvement with comparatively low risk of complications. Met-PET should therefore be considered in all patients who are potential candidates for further surgical intervention, but present no clear target on MRI.PMID:38482632 | DOI:10.1093/ejendo/lvae028 (Source: European Journal of Endocrinology)
Source: European Journal of Endocrinology - March 14, 2024 Category: Endocrinology Authors: Linus Haberbosch James MacFarlane Olympia Koulouri Daniel Gillett Andrew S Powlson Sue Oddy David J Halsall Kevin A Huynh Jonathan Jones Heok K Cheow Joachim Spranger Knut Mai Christian Strasburger Richard J Mannion Mark Gurnell Source Type: research

Real-world experience with 11C-methionine PET in the management of acromegaly
CONCLUSION: In patients with persistent/recurrent acromegaly or occult tumours, Met-PET can facilitate further targeted intervention (surgery/radiosurgery). This led to complete remission in most cases (24/33) or significant improvement with comparatively low risk of complications. Met-PET should therefore be considered in all patients who are potential candidates for further surgical intervention, but present no clear target on MRI.PMID:38482632 | DOI:10.1093/ejendo/lvae028 (Source: European Journal of Endocrinology)
Source: European Journal of Endocrinology - March 14, 2024 Category: Endocrinology Authors: Linus Haberbosch James MacFarlane Olympia Koulouri Daniel Gillett Andrew S Powlson Sue Oddy David J Halsall Kevin A Huynh Jonathan Jones Heok K Cheow Joachim Spranger Knut Mai Christian Strasburger Richard J Mannion Mark Gurnell Source Type: research

Hypogonadism and Neurocognitive Outcomes among Childhood Cancer Survivors
CONCLUSION: Processing speed may be the most vulnerable neurocognitive domain associated with hypogonadism in survivors, while other domains were mainly impacted by cancer-related variables. Our findings support the need for further evaluation of the impact of sex hormone replacement therapy on neurocognitive function.PMID:38468563 | DOI:10.1093/ejendo/lvae027 (Source: European Journal of Endocrinology)
Source: European Journal of Endocrinology - March 12, 2024 Category: Endocrinology Authors: Tomoko Yoshida Tyler Alexander Mengqi Xing Sedigheh Mirzaei S AnnaLynn M Williams Margaret Lubas Tara M Brinkman Wassim Chemaitilly Leslie L Robison Melissa M Hudson Kevin R Krull Angela Delaney Source Type: research

Hypogonadism and Neurocognitive Outcomes among Childhood Cancer Survivors
CONCLUSION: Processing speed may be the most vulnerable neurocognitive domain associated with hypogonadism in survivors, while other domains were mainly impacted by cancer-related variables. Our findings support the need for further evaluation of the impact of sex hormone replacement therapy on neurocognitive function.PMID:38468563 | DOI:10.1093/ejendo/lvae027 (Source: European Journal of Endocrinology)
Source: European Journal of Endocrinology - March 12, 2024 Category: Endocrinology Authors: Tomoko Yoshida Tyler Alexander Mengqi Xing Sedigheh Mirzaei S AnnaLynn M Williams Margaret Lubas Tara M Brinkman Wassim Chemaitilly Leslie L Robison Melissa M Hudson Kevin R Krull Angela Delaney Source Type: research

Hypogonadism and Neurocognitive Outcomes among Childhood Cancer Survivors
CONCLUSION: Processing speed may be the most vulnerable neurocognitive domain associated with hypogonadism in survivors, while other domains were mainly impacted by cancer-related variables. Our findings support the need for further evaluation of the impact of sex hormone replacement therapy on neurocognitive function.PMID:38468563 | DOI:10.1093/ejendo/lvae027 (Source: European Journal of Endocrinology)
Source: European Journal of Endocrinology - March 12, 2024 Category: Endocrinology Authors: Tomoko Yoshida Tyler Alexander Mengqi Xing Sedigheh Mirzaei S AnnaLynn M Williams Margaret Lubas Tara M Brinkman Wassim Chemaitilly Leslie L Robison Melissa M Hudson Kevin R Krull Angela Delaney Source Type: research